On Thursday, Shares of Bank of America Corporation (NYSE:BAC), gained 0.30% to $16.52.
Bank of America Corporation, declared that it has issued its second green bond for $600 million in aggregate principal amount, part of Bank of America’s ongoing commitment to accelerating the transition to a low-carbon economy by advancing renewable energy and promoting energy efficiency.
The bond will assist fund projects under the company’s $70 billion multiyear environmental business commitment. In 2013, the company launched its current 10-year, $50 billion environmental business initiative to advance low-carbon economic solutions through lending, investing and facilitating capital, providing advice and developing solutions for clients around the world. The $50 billion commitment builds upon the company’s initial $20 billion multiyear commitment declared in 2007 and achieved four years ahead of plan.
Bank of America has played a critical role in the development of the rapidly expanding green bond market. In 2013, the company issued the first benchmark-sized corporate green bond – a $500 million offering – and also co-authored the original version of the Green Bonds Principles (GBP), a voluntary set of guidelines to promote integrity in the development of the green bond market.
Bank of America Corporation, through its auxiliaries, provides banking and financial products and services for individual consumers, small and middle market businesses, institutional investors, large corporations, and governments worldwide.
Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT), skyrocketed 57.84% to $6.44, during its last trading session.
Vascular Biogenics, declared that principal investigator, Richard Penson, M.D., M.R.C.P., will present interim data from the ongoing Phase 1/2 clinical trial of lead product candidate, VB-111, for the treatment of platinum-resistant Mullerian cancer, in a poster presentation on Saturday, May 30, 2015 at the American Society for Clinical Oncology (ASCO) 2015 Annual Meeting. The stated data will comprise results in patients with recurrent platinum-resistant Mullerian cancer treated with multiple doses of VB-111 and weekly paclitaxel.
As the first highly targeted anti-angiogenic agent for the specific inhibition of tumor vascular growth to use VBL’s Vascular Targeting System(TM) for cancer therapy, VB-111 has the potential to treat a range of solid tumor indications by selectively targeting the blood vessels required for tumor growth and inducing apoptosis of cells in those blood vessels. VBL recently stated positive, statistically noteworthydata evaluating the efficacy of VB-111 for the treatment of recurrent glioblastoma (rGBM), and anticipates to initiate a pivotal Phase 3 study in rGBM under a Special Protocol Assessment with the U.S. Food and Drug Administration in mid-2015.
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidates comprise VB-111, a gene-based biologic that has accomplished Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer.
At the end of Thursday’s trade, Shares of JPMorgan Chase & Co. (NYSE:JPM), gained 0.81% to $66.05, hitting its highest level.
JPMorgan Chase & Co., declared that it will purchase the mortgage servicing rights (MSRs) for 266,000 high-quality Fannie Mae loans worth an estimated $45 billion from Ocwen Loan Servicing, LLC a wholly-owned partner of Ocwen Financial Corporation. Ocwen formerly declared in a March 2, 2015, release its intention to sell this portfolio of loans.
The buy is consistent with the bank’s desire to enhance the quality and efficiency of the mortgage business. Chase will officially start welcoming new customers— half of which already have another Bank product— later this month and will start on-boarding the loan portfolio on June 1, 2015.
JPMorgan Chase & Co., a financial holding company, provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
Finally, Encana Corporation (NYSE:ECA), ended its last trade with 0.88% gain, and closed at $13.74.
On May 13, RBC Capital Mkts Research Firm downgraded Encana Corporation, from “Outperform” to “Sector Perform”.
On May 12, the company delivered strong results in the first quarter, during which it grew liquids production and cash flow, advanced the development of its four most planned assets and prudently managed its balance sheet. Highlights comprise:
- cash flow of about $495 million, up 31 percent from the fourth quarter of 2014
- liquids production of about 120,700 barrels per day (bbls/d), up 78 percent year-over-year and 13 percent from the fourth quarter of 2014
- noteworthy improvements in well performance, drilling and completion cycle times and cost savings in the company’s four most planned assets, the Montney, Duvernay, Eagle Ford and Permian
- about 80 percent of capital invested in the company’s four most planned assets
- continued efficiencies that have the company on track to deliver the full-year capital savings of $300 million and direct operating cost savings of $75 million embedded in its 2015 guidance
- accomplished a bought deal common share offering in March, and in early April used the net proceeds, together with cash on hand, to redeem about $1.3 billion of long-term debt.
Encana Corporation, together with its auxiliaries, engages in the development, exploration, production, and marketing of natural gas, oil, and natural gas liquids in Canada and the United States. The company owns interests in plays, such as the Montney in northern British Columbia and northwest Alberta; Duvernay in west central Alberta; Clearwater in central and southern Alberta; Deep Panuke in offshore Nova Scotia; Cadomin/Doig in northeast British Columbia; Horn River in northeast British Columbia; and Granite Wash/Doig in northwest Alberta.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
